Patents by Inventor Shashank Mahashabde
Shashank Mahashabde has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20200268685Abstract: The present invention provides pharmaceutical compositions given once daily containing at least one therapeutically active ingredient selected from the group consisting of memantine and a pharmaceutically acceptable salt of memantine, and a pharmaceutically acceptable polymeric matrix carrier. The dosage forms of the invention sustain the release of the therapeutically active agent from about 4 to about 24 hours when said dosage form is exposed to aqueous solutions. following entry of said form into a use environment, wherein said dosage form has a dissolution rate of more than about 80% after passage of about 6 hours to about 12 hours following said entry into said use environment.Type: ApplicationFiled: April 17, 2020Publication date: August 27, 2020Inventors: Suneel K. Rastogi, Niranjan Rao, Antonia Periclou, Wattanaporn Abramowitz, Mahendra G. Dedhiya, Shashank Mahashabde
-
Patent number: 10660868Abstract: The present invention provides pharmaceutical compositions given once daily containing at least one therapeutically active ingredient selected from the group consisting of memantine and a pharmaceutically acceptable salt of memantine, and a pharmaceutically acceptable polymeric matrix carrier. The dosage forms of the invention sustain the release of the therapeutically active agent from about 4 to about 24 hours when said dosage form is exposed to aqueous solutions. following entry of said form into a use environment, wherein said dosage form has a dissolution rate of more than about 80% after passage of about 6 hours to about 12 hours following said entry into said use environment.Type: GrantFiled: July 20, 2016Date of Patent: May 26, 2020Assignee: Forest Laboratories Holdings LimitedInventors: Suneel K Rastogi, Niranjan Rao, Antonia Periclou, Wattanaporn Abramowitz, Mahendra G Dedhiya, Shashank Mahashabde
-
Publication number: 20170172942Abstract: Orally dissolving formulations, e.g., tablets (ODTs) and films (ODFs) comprising memantine and methods of treating conditions, including childhood behavioral disorders and Alzheimer's disease, by administering orally dissolving formulations are provided. The orally dissolving formulations of the present invention may be used to treat various conditions, but is particularly suited to treat childhood behavioral disorders, such as autistic spectrum disorders or combined type Attention-Deficit/Hyperactivity Disorder (ADHD) and also to treat elderly patients suffering from Alzheimer's disease.Type: ApplicationFiled: March 6, 2017Publication date: June 22, 2017Inventors: Shashank Mahashabde, Mahendra G. Dedihya, Anil Chhettry, Ranajoy Sarkar
-
Publication number: 20160324803Abstract: The present invention provides pharmaceutical compositions given once daily containing at least one therapeutically active ingredient selected from the group consisting of memantine and a pharmaceutically acceptable salt of memantine, and a pharmaceutically acceptable polymeric matrix carrier. The dosage forms of the invention sustain the release of the therapeutically active agent from about 4 to about 24 hours when said dosage form is exposed to aqueous solutions. following entry of said form into a use environment, wherein said dosage form has a dissolution rate of more than about 80% after passage of about 6 hours to about 12 hours following said entry into said use environment.Type: ApplicationFiled: July 20, 2016Publication date: November 10, 2016Inventors: Suneel K. Rastogi, Niranjan Rao, Antonia Periclou, Wattanaporn Abramowitz, Mahendra G. Dedhiya, Shashank Mahashabde
-
Publication number: 20150258031Abstract: The present invention provides pharmaceutical compositions given once daily containing at least one therapeutically active ingredient selected from the group consisting of memantine and a pharmaceutically acceptable salt of memantine, and a pharmaceutically acceptable polymeric matrix carrier. The dosage forms of the invention sustain the release of the therapeutically active agent from about 4 to about 24 hours when said dosage form is exposed to aqueous solutions. following entry of said form into a use environment, wherein said dosage form has a dissolution rate of more than about 80% after passage of about 6 hours to about 12 hours following said entry into said use environment.Type: ApplicationFiled: May 27, 2015Publication date: September 17, 2015Inventors: Suneel K. RASTOGI, Niranjan RAO, Antonia PERICLOU, Wattanaporn ABRAMOWITZ, Mahendra G. DEDHIYA, Shashank MAHASHABDE
-
Publication number: 20150238442Abstract: Orally dissolving formulations, e.g., tablets (ODTs) and films (ODFs) comprising memantine and methods of treating conditions, including childhood behavioral disorders and Alzheimer's disease, by administering orally dissolving formulations are provided. The orally dissolving formulations of the present invention may be used to treat various conditions, but is particularly suited to treat childhood behavioral disorders, such as autistic spectrum disorders or combined type Attention-Deficit/Hyperactivity Disorder (ADHD) and also to treat elderly patients suffering from Alzheimer's disease.Type: ApplicationFiled: May 13, 2015Publication date: August 27, 2015Inventors: Shashank Mahashabde, Mahendra G. Dedhiya, Anil Chhettry, Ranajoy Sarkar
-
Publication number: 20150148427Abstract: The present invention provides pharmaceutical compositions given once daily containing at least one therapeutically active ingredient selected from the group consisting of memantine and a pharmaceutically acceptable salt of memantine, and a pharmaceutically acceptable polymeric matrix carrier. The dosage forms of the invention sustain the release of the therapeutically active agent from about 4 to about 24 hours when said dosage form is exposed to aqueous solutions. following entry of said form into a use environment, wherein said dosage form has a dissolution rate of more than about 80% after passage of about 6 hours to about 12 hours following said entry into said use environment.Type: ApplicationFiled: January 28, 2015Publication date: May 28, 2015Inventors: Suneel K. RASTOGI, Niranjan RAO, Antonia PERICLOU, Wattanaporn ABRAMOWITZ, Mahendra G. DEDHIYA, Shashank MAHASHABDE
-
Publication number: 20150065582Abstract: Orally dissolving formulations, e.g., tablets (ODTs) and films (ODFs) comprising memantine and methods of treating conditions, including childhood behavioral disorders and Alzheimer's disease, by administering orally dissolving formulations are provided. The orally dissolving formulations of the present invention may be used to treat various conditions, but is particularly suited to treat childhood behavioral disorders, such as autistic spectrum disorders or combined type Attention-Deficit/Hyperactivity Disorder (ADHD) and also to treat elderly patients suffering from Alzheimer's disease.Type: ApplicationFiled: September 11, 2014Publication date: March 5, 2015Inventors: Shashank Mahashabde, Mahendra G. Dedhiya, Anil Chhettry, Ranajoy Sarkar
-
Publication number: 20140350114Abstract: The invention is directed to formulations of pharmaceutical compounds, such as the Cyclohexylamines and Aminoadamantanes which have antimicrobial properties. In particular, it is directed to aqueous based formulations with reduced amounts of preservatives which allow safe and convenient administration and flexible dosing and which, in the case of oral formulations, are easy to swallow. Optionally, the compositions contain components that provide the requisite stability and shelf life while reducing or avoiding incrustation of the composition around the container closure which leads to leaks and difficulty in opening the container.Type: ApplicationFiled: August 7, 2014Publication date: November 27, 2014Inventors: Mahendra G. DEDHIYA, Shashank MAHASHABDE, Yan YANG, Anshu GOEL, Erhard SEILLER, Bernhard HAUPTMEIER
-
Publication number: 20140213659Abstract: The present invention provides pharmaceutical compositions given once daily containing at least one therapeutically active ingredient selected from the group consisting of memantine and a pharmaceutically acceptable salt of memantine, and a pharmaceutically acceptable polymeric matrix carrier. The dosage forms of the invention sustain the release of the therapeutically active agent from about 4 to about 24 hours when said dosage form is exposed to aqueous solutions. following entry of said form into a use environment, wherein said dosage form has a dissolution rate of more than about 80% after passage of about 6 hours to about 12 hours following said entry into said use environment.Type: ApplicationFiled: March 28, 2014Publication date: July 31, 2014Applicant: Forest Laboratories Holdings Ltd.Inventors: Suneel K. RASTOGI, Niranjan RAO, Antonia PERICLOU, Wattanaporn ABRAMOWITZ, Mahendra G. DEDHIYA, Shashank MAHASHABDE
-
Publication number: 20130310460Abstract: The present invention provides pharmaceutical compositions given once daily containing at least one therapeutically active ingredient selected from the group consisting of memantine and a pharmaceutically acceptable salt of memantine, and a pharmaceutically acceptable polymeric matrix carrier. The dosage forms of the invention sustain the release of the therapeutically active agent from about 4 to about 24 hours when said dosage form is exposed to aqueous solutions. following entry of said form into a use environment, wherein said dosage form has a dissolution rate of more than about 80% after passage of about 6 hours to about 12 hours following said entry into said use environment.Type: ApplicationFiled: July 23, 2013Publication date: November 21, 2013Applicant: Forest Laboratories Holdings Ltd.Inventors: Suneel K. RASTOGI, Niranjan RAO, Antonia PERICLOU, Wattanaporn ABRAMOWITZ, Mahendra G. DEDHIYA, Shashank MAHASHABDE
-
Publication number: 20130012593Abstract: The present invention provides pharmaceutical compositions given once daily containing at least one therapeutically active ingredient selected from the group consisting of memantine and a pharmaceutically acceptable salt of memantine, and a pharmaceutically acceptable polymeric matrix carrier. The dosage forms of the invention sustain the release of the therapeutically active agent from about 4 to about 24 hours when said dosage form is exposed to aqueous solutions, following entry of said form into a use environment, wherein said dosage form has a dissolution rate of more than about 80% after passage of about 6 hours to about 12 hours following said entry into said use environment.Type: ApplicationFiled: September 14, 2012Publication date: January 10, 2013Applicant: Forest Laboratories Holdings Ltd.Inventors: Suneel K. Rastogi, Niranjan Rao, Antonia Periclou, Wattanaporn Abramowitz, Mahendra G. Dedhiya, Shashank Mahashabde
-
Publication number: 20120238631Abstract: The invention is directed to formulations of pharmaceutical compounds, such as the Cyclohexylamines and Aminoadamantanes which have antimicrobial properties. In particular, it is directed to aqueous based formulations with reduced amounts of preservatives which allow safe and convenient administration and flexible dosing and which, in the case of oral formulations, are easy to swallow. Optionally, the compositions contain components that provide the requisite stability and shelf life while reducing or avoiding incrustation of the composition around the container closure which leads to leaks and difficulty in opening the container.Type: ApplicationFiled: April 26, 2012Publication date: September 20, 2012Applicant: MERZ PHARMA GmbH & CO. KGaAInventors: Mahendra G. Dedhiya, Shashank Mahashabde, Yan Yang, Anshu Goel, Erhard Seiller, Bernhard Hauptmeier
-
Patent number: 8263600Abstract: A liquid suspension comprising an antifungally effective amount of the micronized compound represented by the chemical structural formula I: at least one thickening agent, a non-ionic surfactant, and a pharmaceutically acceptable liquid carrier is disclosed.Type: GrantFiled: June 15, 2011Date of Patent: September 11, 2012Assignee: Merck Sharp & Dohme Corp.Inventors: Stefan Sharpe, Joel Sequeira, David Harris, Shashank Mahashabde
-
Publication number: 20120004318Abstract: The present invention provides pharmaceutical compositions given once daily containing at least one therapeutically active ingredient selected from the group consisting of memantine and a pharmaceutically acceptable salt of memantine, and a pharmaceutically acceptable polymeric matrix carrier. The dosage forms of the invention sustain the release of the therapeutically active agent from about 4 to about 24 hours when said dosage form is exposed to aqueous solutions. following entry of said form into a use environment, wherein said dosage form has a dissolution rate of more than about 80% after passage of about 6 hours to about 12 hours following said entry into said use environment.Type: ApplicationFiled: September 15, 2011Publication date: January 5, 2012Applicant: FOREST LABORATORIES HOLDINGS LTD.Inventors: Suneel K. Rastogi, Niranjan Rao, Antonia Periclou, Wattanaporn Abramowitz, Mahendra G. Dedhiya, Shashank Mahashabde
-
Patent number: 8039009Abstract: The present invention provides pharmaceutical compositions given once daily containing at least one therapeutically active ingredient selected from the group consisting of memantine and a pharmaceutically acceptable salt of memantine, and a pharmaceutically acceptable polymeric matrix carrier. The dosage forms of the invention sustain the release of the therapeutically active agent from about 4 to about 24 hours when said dosage form is exposed to aqueous solutions. following entry of said form into a use environment, wherein said dosage form has a dissolution rate of more than about 80% after passage of about 6 hours to about 12 hours following said entry into said use environment.Type: GrantFiled: June 16, 2005Date of Patent: October 18, 2011Assignee: Forest Laboratories Holdings LimitedInventors: Suneel K. Rastogi, Niranjan Rao, Antonia Periclou, Wattanaporn Abramowitz, Mahendra G. Dedhiya, Shashank Mahashabde
-
Publication number: 20110244004Abstract: A liquid suspension comprising an antifungally effective amount of the micronized compound represented by the chemical structural formula I: at least one thickening agent, a non-ionic surfactant, and a pharmaceutically acceptable liquid carrier is disclosed.Type: ApplicationFiled: June 15, 2011Publication date: October 6, 2011Applicant: Schering-Plough CorporationInventors: Stefan Sharpe, Joel Sequeira, David Harris, Shashank Mahashabde
-
Publication number: 20110046232Abstract: Orally dissolving formulations, e.g., tablets (ODTs) and films (ODFs) comprising memantine and methods of treating conditions, including childhood behavioral disorders and Alzheimer's disease, by administering orally dissolving formulations are provided. The orally dissolving formulations of the present invention may be used to treat various conditions, but is particularly suited to treat childhood behavioral disorders, such as autistic spectrum disorders or combined type Attention-Deficit/Hyperactivity Disorder (ADHD) and also to treat elderly patients suffering from Alzheimer's disease.Type: ApplicationFiled: September 23, 2010Publication date: February 24, 2011Applicant: FOREST LABORATORIES HOLDINGS LTD.Inventors: Shashank Mahashabde, Mahendra G. Dedhiya, Anil Chhettry, Ranajoy Sarkar
-
Publication number: 20100035995Abstract: The invention is directed to formulations of pharmaceutical compounds, such as the Cyclohexylamines and Aminoadamantanes which have antimicrobial properties. In particular, it is directed to aqueous based formulations with reduced amounts of preservatives which allow safe and convenient administration and flexible dosing and which, in the case of oral formulations, are easy to swallow. Optionally, the compositions contain components that provide the requisite stability and shelf life while reducing or avoiding incrustation of the composition around the container closure which leads to leaks and difficulty in opening the container.Type: ApplicationFiled: October 14, 2009Publication date: February 11, 2010Applicant: MERZ PHARMA GMBH & CO. KGAAInventors: Mahendra G. Dedhiya, Shashank Mahashabde, Yan Yang, Anshu Goel, Erhard Seiller, Bernhard Hauptmeier
-
Publication number: 20080305164Abstract: Crystalline particles of escitalopram oxalate with a particle size of at least 40 ?m is disclosed. Method for the manufacture of said crystalline particles and pharmaceutical compositions comprising said crystalline particles are also disclosed.Type: ApplicationFiled: August 22, 2008Publication date: December 11, 2008Applicant: H. LUNDBECK A/SInventors: Troels Volsgaard Christensen, Ken Liljegren, Michiel Onne Elema, Lene Andresen, Shashank Mahashabde, Sebastian P. Assenza